Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
hVIVO PLC on Monday said it had signed a letter of intent to run phase 3 trials on ILiAD Biotechnologies LLC’s whooping cough vaccine.
The London-based medical research contractor is slated to test BPZE1, the lead vaccine candidate of the Florida-based biotechnology firm. BPZE1 targets bordetella pertussis, a type of bacteria which causes whooping cough.
hVIVO described the deal with ILiAD as a ‘landmark study’ in its human challenge portfolio. This model of testing means researchers expose volunteers to the bacteria, rather than waiting to test naturally-infected patients.
The two companies are yet to finalise the deal, though testing is expected to commence in the second-half of 2025.
hVIVO shares rose 8.8% to 21.33 pence on Monday morning in London.
The news comes amid one of whooping cough’s cyclical outbreaks, according to hViVO. Global vaccination rates for the disease are estimated at 84%. Still in 2024, the US Centre for Disease & Prevention reported a sixfold annual increase in cases as part of a ‘return to pre-pandemic patterns’.
ILiAD Chief Executive Keith Rubin commented: ‘By leveraging hVIVO’s extensive experience and expertise in human challenge trials, we plan to generate robust pivotal clinical data to support global marketing authorisation applications for BPZE1, a vaccine with the potential to address a major unmet medical need.’
Copyright 2025 Alliance News Ltd. All Rights Reserved.